International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financi...(used by changes in accountingstandards r...),Health

Steve T. Laflin, President and CEO of International Isotopes Inc. said, "Most of our core business segments continue to demonstrate positive growth. The increase in operations expenses are the result of newly included depreciation expense and implementation of new accounting standard costing requirements for employee stock options. The Company also incurred significant legal expenses related to patent development and the protection of additional intellectual property developed by our Fluorine Products Division. I am confident the investments we are making in intellectual property and the business model we have developed and are strategically implementing, should produce some significant positive accomplishments in coming quarters. We are committed to building shareholder value."

International Isotopes Inc.

Three Months Ended Sept. 30 Nine Months ended Sept. 30

2007 2006 2007 2006

Sales $1,486,112 $1,458,260 $3,952,049 $3,641,098

Gross Profit $689,849 $605,976 $1,618,879 $1,673,696

Total Operating

Expense $970,115 $722,463 $2,756,052 $2,106,958

Operating (Loss) ($280,266) ($116,487) ($1,137,173) ($433,262)

Other Income

(Expense) $3,979 ($49,254) ($9,108) ($135,900)

Net (Loss) ($276,287) ($165,741) ($1,146,281) ($569,162)

Net (Loss) Per

Common Share ($0.00) ($ 0.00) ($0.00) ($0.00)

Weighted Ave.

Shares Outstanding 247,646,540 213,184,707 235,378,328 211,078,457

About International Isotopes Inc.'/>"/>